Technique allows for radiation-free detection of tumors, study finds

Researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital Stanford have developed a way to scan young cancer patients' bodies for tumors without exposing them to radiation. The technique could reduce patients' risk of developing secondary cancers later in life.

The new method, described in a scientific paper that will be published Feb. 18 in The Lancet Oncology, is a modification of magnetic resonance imaging that employs a novel contrast agent to find tumors. The MRI-based method is as effective as cancer-detection scans that use ionizing radiation—specifically, positron emission tomography-computed tomography—the researchers found.

Although whole-body PET-CT technology provides essential information for detecting cancer, it has one big drawback: A single scan exposes the patient to as much radiation as 700 chest X-rays. This exposure is especially risky for children and teenagers, who are more vulnerable to radiation than adults because they are still growing. Children are also more likely to live long enough to develop a second cancer.

"I'm excited about having an imaging test for that requires zero radiation exposure," said senior author Heike Daldrup-Link, MD, associate professor of radiology at Stanford and a diagnostic radiologist at the hospital. "That is a big deal."

The research team compared the modified MRI technique to standard PET-CTs in 22 patients ages 8 to 33 who had lymphoma or sarcoma. These cancers originate in the immune system and the bones, respectively. Both cancers can spread throughout tissues such as bone marrow, , liver and spleen.

In the past, several hurdles prevented physicians from using whole-body MRIs to look for tumors. The scans take up to two hours. A whole-body PET-CT, however, takes only a few minutes. (It combines PET images taken by monitoring the metabolism of radioactive glucose with CT images, which are essentially a series of X-rays from different angles.) More importantly, in many organs, MRI does not distinguish healthy from cancerous tissue. And existing contrast agents—chemicals injected into the body to make tumors visible—leave the tissues too quickly to be used in a lengthy, whole-body MRI.

To find tumors via MRI, the Stanford team used a new contrast agent consisting of of iron. Injections of these iron nanoparticles are approved by the Food and Drug Administration to treat anemia, and the researchers obtained FDA permission for the experimental use. The nanoparticles are retained in the body for many days. On MRIs, they cause blood vessels to appear brighter, providing anatomic landmarks. The nanoparticles also cause healthy bone marrow, lymph nodes, liver and spleen to appear darker, making tumors stand out.

The images generated from the experimental MRIs provided comparable information to the PET-CT scans that study subjects received as part of their care. The PET-CTs detected 163 of 174 total tumors in the 22 patients; the MRIs found 158 of 174 tumors. The two methods had similar levels of sensitivity, specificity and diagnostic accuracy.

"We were able to find a new way to integrate anatomical and physiological MRI information and make it more efficient," said Christopher Klenk, MD, a postdoctoral scholar and the paper's lead author.

None of the patients experienced adverse reactions to the iron nanoparticles, though the FDA has previously noted a small risk of allergic reaction to the nanoparticles' coating. (It's rare for patients to have adverse reactions to other , too.)

Radiologists at several academic hospitals are searching for ways to reduce children's , Daldrup-Link said, adding that she is sharing the new technique with colleagues around the country.

"Some type of whole-body MRI imaging test is available at many big children's hospitals right now," she said, adding that for such techniques to be widely adopted, doctors are asking for evidence that whole-body MRI does the job. "It's slowly entering clinical practice, but clinicians are cautious and want to be convinced," she added. The other barrier to wide adoption of MRI-based tests is lack of a billing code, a hurdle the researchers hope will soon be resolved. But there are no technologic obstacles to use of the new technique.

"It's really exciting that this will soon be clinically applicable," Daldrup-Link said.

Future research will aim to validate the MRI-based method in larger, more diverse groups of cancer patients, as well as examine its possible use for monitoring tumors over the course of cancer treatment. The MRI-based method also holds promise for scanning patients after their treatment is complete, when the ability to monitor them without radiation would be especially valuable.

add to favorites email to friend print save as pdf

Related Stories

PET/MR effective for imaging recurrent prostate cancer

Jun 11, 2013

When prostate cancer makes a comeback, it becomes increasingly important to have exceptional imaging available to find all possible regions where cancer has spread to other parts of the body, or metastasized, in order to ...

FDA approval for Siemens PET Scan - MRI combo

Jun 13, 2011

(Medical Xpress) -- The Siemens Biograph mMR system, offering both a PET scan and an MRI that work simultaneously, has been given approval by the FDA. The idea behind this machine and the ability to run both tests at the ...

FDA clears Siemens' 2-in-1 medical scanner

Jun 10, 2011

(AP) -- The Food and Drug Administration says it has cleared the first medical imaging device to simultaneously perform two powerful scans used to diagnose a wide variety of diseases and ailments.

Combination PET-MRI scanner expands imaging frontiers

Feb 16, 2012

(Medical Xpress) -- Scientists at Washington University School of Medicine are using a new imaging device that simultaneously performs positron-emission tomography (PET) and magnetic resonance imaging (MRI) scans, producing ...

Recommended for you

Study pinpoints microRNA tied to colon cancer tumor growth

13 hours ago

Researchers at the University of Minnesota have identified microRNAs that may cause colon polyps from turning cancerous. The finding could help physicians provide more specialized, and earlier, treatment before colon cancer ...

Obesity tied to higher cancer risk for CRC survivors

14 hours ago

(HealthDay)—Colorectal cancer (CRC) patients who are overweight or obese when diagnosed appear to face a slightly higher risk for developing a second weight-related cancer, according to research published ...

User comments